Since its inception in 1976, *Cancer Immunology, Immunotherapy* (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. CII is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.

In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

- “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
- “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunología-Grupo Española de InmunoTerapia (SEI-GEIT).

Impact Factor: 4.900 (2018), Journal Citation Reports®

On the homepage of *Cancer Immunology, Immunotherapy* at [springer.com](http://springer.com) you can

- Sign up for our Table of Contents Alerts
- Get to know the complete Editorial Board
- Find submission information